Anti-HLA sensitization in extensively burned patients: Extent, associated factors, and reduction in potential access to vascularized composite allotransplantation

Transplant International

Volumn 28, Issue 5, 2015, Pages 582-593

  Duhamel, Patrick ^a   Suberbielle, Caroline ^b   Grimbert, Philippe ^b   Leclerc, Thomas ^a   Jacquelinet, Christian ^c   Audry, Benoit ^c   Bargues, Laurent ^c   Charron, Dominique ^b   Bey, Eric ^a   Lantieri, Laurent ^d   Hivelin, Mikael ^d  

^a PERCY MILITARY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Agence de la Biomedecine   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anti HLA antibodies; Composite tissue allograft; Donor recipient matching; Sensitization; Simulated allocation modelling; Skin allograft

Indexed keywords

ANTIGEN; COMPLEMENT; GLYCEROL; HLA ANTIBODY; ANTIBODY; COMPLEMENT COMPONENT C1Q; HLA ANTIGEN;

ADULT; ARTICLE; BIVARIATE ANALYSIS; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; BODY SURFACE; BURN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPLEMENT FIXATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CRYOPRESERVATION; DISEASE SEVERITY; ERYTHROCYTE CONCENTRATE; FEMALE; FLOW MEASUREMENT; HISTORY; HLA TYPING; HUMAN; MALE; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SERUM; SINGLE ANTIGEN FLOW BEAD ANALYSIS; SKIN ALLOGRAFT; SKIN SENSITIZATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; ADOLESCENT; ALLOGRAFT; BURNS; CHEMISTRY; CHILD; CYTOLOGY; ERYTHROCYTE; HEALTH CARE DELIVERY; IMMUNOPHENOTYPING; MIDDLE AGED; SKIN TRANSPLANTATION; YOUNG ADULT;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIBODIES; BLOOD TRANSFUSION; BURNS; CHILD; COMPLEMENT C1Q; CROSS-SECTIONAL STUDIES; CRYOPRESERVATION; ERYTHROCYTES; FEMALE; GLYCEROL; HEALTH SERVICES ACCESSIBILITY; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; SKIN TRANSPLANTATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; YOUNG ADULT;

EID: 84928357956     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12540     Document Type: Article

References (76)

1. Lantieri L, Meningaud JP, Grimbert P, et al.,. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet 2008; 372: 639.
2. Siemionow M, Papay F, Alam D, et al.,. Near-total human face transplantation for a severely disfigured patient in the USA. Lancet 2009; 374: 203.
3. Lantieri L, Hivelin M, Audard V, et al.,. Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes. Am J Transplant 2011; 11: 367.
4. Pomahac B, Pribaz J, Eriksson E, et al.,. Three patients with full facial transplantation. N Engl J Med 2012; 366: 715.
5. Petruzzo P, Lanzetta M, Dubernard JM, et al.,. The international registry on hand and composite tissue transplantation. Transplantation 2010; 90: 1590.
6. Petruzzo P, Dubernard JM,. The international registry on hand and composite tissue allotransplantation. Clin Transpl 2011; 00: 247.
7. Khalifian S, Brazio PS, Mohan R, et al.,. Facial transplantation: the first 9 years. Lancet 2014; 384: 2153.
8. Carty MJ, Hivelin M, Dumontier C, et al.,. Lessons learned from simultaneous face and bilateral hand allotransplantation. Plast Reconstr Surg 2013; 132: 423.
9. Chandraker A, Arscott R, Murphy GF, et al.,. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant 2014; 14: 1446.
10. Weissenbacher A, Hautz T, Zelger B, et al.,. Antibody-mediated rejection in hand transplantation. Transpl Int 2014; 27: e13.
11. Leto Barone AA, Sun Z, Montgomery RA, Lee WP, Brandacher G,. Impact of donor-specific antibodies in reconstructive transplantation. Expert Rev Clin Immunol 2013; 9: 835.
12. Unadkat JV, Schneeberger S, Goldbach C, et al.,. Investigation of antibody-mediated rejection in composite tissue allotransplantation in a rat limb transplant model. Transplant Proc 2009; 41: 542.
13. Wu S, Xu H, Chen B, et al.,. Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts. Transplantation 2011; 92: 627.
14. Pomahac B, Pribaz J, Eriksson E, et al.,. Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft. Am J Transplant 2011; 11: 386.
15. Fratianne RB, Brandt CP,. Determining when care for burns is futile. J Burn Care Rehabil 1997; 18: 262.
16. Ismail A, Long J, Moiemen N, Wilson Y,. End of life decisions and care of the adult burn patient. Burns 2011; 37: 288.
17. Sachs A, Watson J,. Four years' experience at a specialised burns centre. The McIndoe Burns Centre 1965-68. Lancet 1969; 1: 718.
18. Gaucher S, Elie C, Verola O, Jarraya M,. Viability of cryopreserved human skin allografts: effects of transport media and cryoprotectant. Cell Tissue Banking 2012; 13: 147.
19. Loupy A, Suberbielle-Boissel C, Hill GS, et al.,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
20. Lefaucheur C, Loupy A, Hill GS, et al.,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
21. Jacquelinet C, Audry B, Golbreich C, et al.,. Changing kidney allocation policy in France: the value of simulation. AMIA Annu Symp Proc 2006; 374.
22. Bielmann D, Hönger G, Lutz D, Mihatsch M, Steiger J, Schaub S,. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
23. Zachary AA, Braun WE,. Calculation of a predictive value for transplantation. Transplantation 1985; 39: 316.
24. Cecka JM,. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26.
25. Grout P, Horsley M, Touquet R,. Epidemiology of burns presenting to an accident and emergency department. Arch Emerg Med 1993; 10: 100.
26. Druery M, Brown TL, Muller M,. Long term functional outcomes and quality of life following severe burn injury. Burns 2005; 31: 692.
27. Anzarut A, Chen M, Shankowsky H, Tredget EE,. Quality-of-life and outcome predictors following massive burn injury. Plast Reconstr Surg 2005; 116: 791.
28. Miller PL,. Application of a model to guide ethical decision making in burn treatment. J Burn Care Rehabil 2000; 21: 433.
29. Murphy AD, Healy C, Purcell E, Fitzgerald E, Kelly JL,. An assessment of burn care professionals' attitudes to major burn. Burns 2008; 34: 512.
30. Gibson T, Medawar PB,. The fate of skin homografts in man. J Anat 1943; 77: 299.
31. Criswell KK, Gamelli RL,. Establishing transfusion needs in burn patients. Am J Surg 2005; 189: 324.
32. Jackson D,. A clinical study of the use of skin homografts for burns. Br J Plast Surg 1954; 7: 26.
33. Vo A, Cao K, Lai C,. Long term outcomes in highly-HLA sensitized patients receiving desensitization with IVIG and single-dose rituximab. Am J Transplant 2009; 9: 557.
34. Gerlach UA, Schoenemann C, Lachmann N, Koch M, Pascher A,. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Transpl Int 2011; 24: e43.
35. LaMattina JC, Mezrich JD, Hofmann RM, et al.,. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int 2012; 25: 518.
36. Fehr T, Gaspert A,. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623.
37. Vo AA, Lukovsky M, Toyoda M, et al.,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
38. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS,. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719.
39. Lefaucheur C, Antoine C, Suberbielle C, Glotz D,. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592.
40. Racusen LC, Leffell MS,. C1q-binding antibodies in kidney transplantation. N Engl J Med 2013; 369: 1266.
41. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB,. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
42. Chen G, Sequeira F, Tyan DB,. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849.
43. Bartel G, Wahrmann M, Schwaiger E, et al.,. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013; 26: 121.
44. Kanitakis J, McGregor B, Badet L, et al.,. Absence of c4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study. Transplantation 2007; 84: 265.
45. Cendales LC, Kanitakis J, Schneeberger S, et al.,. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8: 1396.
46. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12.
47. Chin C, Chen G, Sequeria F, et al.,. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158.
48. Ata P, Canbakan M, Kara M, Ozel L, Unal E, Titiz MI,. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization. Transplant Proc 2012; 44: 1652.
49. Freitas MC, Rebellato LM, Ozawa M, et al.,. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113.
50. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD,. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618.
51. Loupy A, Lefaucheur C, Vernerey D, et al.,. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215.
52. Crespo M, Torio A, Mas V, et al.,. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol 2013; 29: 28.
53. Schaub S, Honger G, Koller MT, Liwski R, Amico P,. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014; 98: 387.
54. Zeevi A, Marrari M, Feingold B, Webber S, Duquesnoy RJ,. Human leukocyte antigen epitope analysis to assess complement- and non-complement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol 2012; 73: 48.
55. Llorente S, Boix F, Eguia J, et al.,. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. Transplant Proc 2012; 44: 2535.
56. Lachmann N, Todorova K, Schulze H, Schonemann C,. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013; 95: 694.
57. Tait BD, Susal C, Gebel HM, et al.,. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19.
58. D'Apice AJ, Morris PJ,. The role of antibody-dependent cell-mediated cytotoxicity in renal allograft rejection. Transplantation 1974; 18: 20.
59. Jackson AM, Lucas DP, Melancon JK, Desai NM,. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011; 92: 54.
60. Valenzuela NM, Reed EF,. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034: 41.
61. Bentall A, Tyan DB, Sequeira F, et al.,. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27: 1235.
62. Hyun J, Park KD, Yoo Y, et al.,. Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplant Proc 2012; 44: 222.
63. Murray JE,. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg 1971; 47: 425.
64. Cinamon U, Eldad A, Chaouat M, et al.,. A simplified testing system to evaluate performance after transplantation of human skin preserved in glycerol or in liquid nitrogen. J Burn Care Rehabil 1993; 14: 435.
65. Richters CD, Hoekstra MJ, van Baare J, du Pont JS, Kamperdijk EW,. Immunogenicity of glycerol-preserved human cadaver skin in vitro. J Burn Care Rehabil 1997; 18: 228.
66. Dhennin C, Desbois I, Yassine A, Benissad H, Lignee J,. Utilisation of glycerolised skin allografts in severe burns. Burns 2002; 28 (Suppl 1): S21.
67. Wachtel TL, Ninnemann J, Fisher JC, Frank HA, Inancsi W,. Viability of frozen allografts. Am J Surg 1979; 138: 783.
68. Awada T, Jacquelinet C, Audry B, et al.,. Correspondance de sexe dans les allotransplantations de face ou d'avant-bras: Fondements et conséquences sur l'accès aux greffons. Chirurgie Plastique Reconstructrice et Esthetique. Faculté de médecine, Université de Strasbourg, Paris, Strasbourg, Lyon, 2014.
69. Welters MJ, Oei FB, Witvliet MD, et al.,. A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts. Hum Immunol 2002; 63: 1019.
70. Hawkins JA, Hillman ND, Lambert LM, et al.,. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg 2003; 126: 247.
71. da Costa FD, Dohmen PM, Duarte D, et al.,. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg 2005; 27: 572.
72. Heimbach D, Luterman A, Burke J, et al.,. Artificial dermis for major burns. A multi-center randomized clinical trial. Ann Surg 1988; 208: 313.
73. Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD,. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997; 18: 43.
74. Sun T, Han Y, Chai J, Yang H,. Transplantation of microskin autografts with overlaid selectively decellularized split-thickness porcine skin in the repair of deep burn wounds. J Burn Care Res 2011; 32: e67.
75. Diaz Varela I, Sanchez Mozo P, Centeno Cortes A, Alonso Blanco C, Valdes Canedo F,. Cross-reactivity between swine leukocyte antigen and human anti-HLA-specific antibodies in sensitized patients awaiting renal transplantation. J Am Soc Nephrol 2003; 14: 2677.
76. Cooper DK, Tseng YL, Saidman SL,. Alloantibody and xenoantibody cross-reactivity in transplantation. Transplantation 2004; 77: 1.